pulmonary fibrosis News
-
Inversago Pharma presents data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), currently held in Barcelona, Spain and online. These data show that Inversago’s INV-101 (zevaquenabant), a small molecule, peripherally-acting CB1 ...
-
NuMedii, Inc. Announces New Partnership To Discover and Advance New Treatments for Idiopathic Pulmonary Fibrosis
MENLO PARK, Calif., April 11, 2017 – NuMedii, Inc. today announced the formation of a strategic partnership with Three Lakes Partners, LLC, to discover and advance new treatments for idiopathic pulmonary fibrosis (IPF) based on NuMedii’s Big Data intelligence technology. Idiopathic pulmonary fibrosis is a rare chronic progressive and usually fatal interstitial lung disease for which ...
-
Lung Therapeutics, Inc. Raises $36 Million in Series C Financing to Advance Clinical Pipeline
Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, announced today the closing of $36 million Series C financing. To date, Lung Therapeutics has raised a total of $53 million in outside funding. The Series C funding will finance the company’s next stage of growth, including the advancement and completion of ...
-
AdAlta granted Indian patent protecting AD-214
AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to announce that its first Indian patent relating to lead program, AD-214, has been granted by the Indian Patent Office. Patent Number 398125, entitled "CXCR4 binding molecules", has an expiry date of 8 January 2036. The new patent protects the i-body ...
-
BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca’s Portfolio
Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021 London, 15 December 2021: BenevolentAI, a leading ...
By Benevolent
-
Lung Therapeutics, Inc. Announces New Chief Financial Officer and Board Member
Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, announced today the hiring of Charles T. Garner as Chief Financial Officer and the appointment of R.A. Session, II, to the company’s Board of Directors. Garner and Session both join Lung Therapeutics at a time of growth and expansion for the company. In the ...
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
Inversago Pharma to participate to BIO International Convention 2022 in San Diego, CA
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. François Ravenelle, PhD, Chief Executive Officer of Inversago; Glenn D. Crater, MD, Chief Medical Officer; and, ...
-
Lung Therapeutics Announces Appointment of Cory M. Hogaboam, Ph.D., as Chief Scientific Officer
Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of Cory M. Hogaboam, Ph.D., as Chief Scientific Officer. As CSO, Dr. Hogaboam will be responsible for guiding Lung Therapeutics’ scientific research and will serve as a key member of the company’s executive ...
-
Inversago Pharma to present preclinical data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), to be held in Barcelona, Spain and online. Abstract: “INV-101, a cannabinoid receptor-1 inverse agonist, reduces fibrosis in a bleomycin mouse model ...
-
Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers
LTI-03, a Caveolin-1-related peptide, addresses both inhibition of pro-fibrotic signaling, as well as survival of critical epithelial cells LTI-03 is formulated as a dry powder for direct-to-lung administration Lung Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing innovative treatments for the treatment of orphan pulmonary and fibrosis indications, ...
-
Inversago Pharma to participate to upcoming Bio€quity Europe 2022 to be held on May 16-18 in Milan, Italy and on May 23-24 virtually
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer and Glenn D. Crater, MD, FCCP, Chief Medical Officer, will take part to the Presenting Company Class of 2022 at Bio€quity Europe. Details are as follows: MAY 16-18, 2022 ...
-
Inversago Pharma Awarded the Promising Health Biotech Company of the Year Gold Leaf Award at the BIONATION Conference in Ottawa
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the ?Promising Health Biotech Company of the Year' Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada. An initiative of BIOTECanada, the national industry association, coveted Gold ...
-
NuMedii Advances IPF Personalized Medicine with New Advisory Board to Guide AI Approach
NuMedii is advancing the field of personalized medicine for idiopathic pulmonary fibrosis (IPF) by creating a new advisory board that includes some of the world’s leading specialists in interstitial lung disease to guide a new approach to drug discovery based on artificial intelligence (AI). The California-based company has been exploring the potential of big data and AI since 2010 to ...
-
Third Pole Therapeutics to Participate in H.C. Wainwright BioConnect and BIO Partnering at JPM during J.P. Morgan 40th Annual Healthcare Conference
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference. Details of the events and presentation are as ...
-
World’s Leading Lung Disease Experts Join NuMedii’s Idiopathic Pulmonary Fibrosis Advisory Board
MENLO PARK, Calif., January 8, 2018 – NuMedii, Inc. today announced the formation of an Idiopathic Pulmonary Fibrosis (IPF) Advisory Board consisting of the world’s leading experts in interstitial lung disease: Naftali Kaminski, MD; David A. Schwartz, MD; Kevin Brown, MD; Toby Maher, MD, PhD; Gisli Jenkins, MD, PhD; Zea Borok, MD; and, Paul Wolters, MD. The newly formed Board of ...
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release ...
By CohBar, Inc.
-
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’s portfolio. Novel chronic kidney disease (CKD) target from the partnership enters AstraZeneca’s portfolio AI-generated ...
By Benevolent
-
Haymarket Medical Network Launches Rare Disease Advisor
Haymarket Medical Network today launched Rare Disease Advisor, a new digital resource for healthcare professionals (HCPs) to help them recognize, diagnose, refer and treat rare diseases. RareDiseaseAdvisor.com fills an information gap for HCPs by providing difficult to find information on rare diseases in one convenient place, enabling physicians and care teams with a comprehensive digital ...
-
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases
LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting joint research with Mayo Clinic for NASH drugs since 2021, and this new collaboration is an agreement signed under the leadership of Nicholas F. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you